Clindamycin hydrochloride (Clinimycin HCl) inhibits protein synthesis by acting on the 50S ribosomal. It is the hydrochloride salt form of clindamycin, a semi-synthetic, chlorinated broad-spectrum antibiotic produced by chemical modification of lincomycin. Clindamycin hydrochloride(Clinimycin HCl) is used as a solid in capsules.

Clindamycin是一种经典的细菌蛋白质合成抑制剂，它通过结合到50S核糖体亚基的23S核糖体RNA上发挥作用。[1]

Clindamycin hydrochloride 口服给犬类后可快速吸收，平均吸收时间 (MAT) 为 0.87 小时，生物利用度为 72.55%。无论是通过静脉注射 (IV) 还是口服给药，Clindamycin hydrochloride 在犬类体内的总清除率 (CL) 分别为 0.503 和 0.458 L/h/kg。其在稳态时的分布容积 (IV) 为 2.48 L/kg，表明克林默素在体液和组织中分布广泛。Clindamycin hydrochloride 在静脉注射和口服给药后的血清浓度能在大约 10 小时内保持在 0.5 μg/mL 以上。[1] Clindamycin hydrochloride 显著减少犬类口腔异味，自基线水平起至 42 天。同时，它也显著降低了牙齿菌斑、牙石和牙龈出血。[2] 在超声牙石清除、根面平整及抛光 (USRP) 后，Clindamycin hydrochloride (2.5 mg/lb) 显著影响牙周病的牙菌斑和袋深度指标，但对犬类牙龈炎无明显效果。[3] 在 14 至 28 天内治疗，Clindamycin hydrochloride 使犬类浅表性细菌性皮肤炎的完全缓解率达到 71.4% (15/21)。[4]

In vitro potency assays: After RO4929097 is used, the Aβ peptides are measured by ECL assays using a variety of anti-Aβ antibodies and an Origen 1.5 Analyzer. The 4 g8 murine mAb binds an epitope in the Aβ peptide (within amino acids 18–21) that is immediately distal to the α-secretase cleavage site. The G2–10 murine mAb binds the C terminus that is exposed after γ-secretase-mediated cleavage to generate amino acid 40 of the Aβ40 peptide. The FCA3542 rabbit antibody binds the C terminus that is exposed after γ-secretase-mediated cleavage to generate amino acid 42 of the Aβ42 peptide. The 4 g8 mAb is biotinylated with biotin-LC-sulfo-N-hydroxysuccinimide-ester. The G2–10 and FCA3542 antibodies are ruthenylated with TAG-N-hydroxysuccinimide ester. Aβ(x-40) is detected with biotinylated 4 g8 and ruthenylated G2–10. Aβ(x-42) is detected with biotinylated 4 g8 and ruthenylated FCA3542.